

## **BAISHIDENG PUBLISHING GROUP INC**

8226 Regency Drive, Pleasanton, CA 94588, USA Telephone: +1-925-223-8242 Fax: +1-925-223-8243 E-mail: bpgoffice@wjgnet.com http://www.wjgnet.com

## ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology ESPS manuscript NO: 31069 Title: Emerging Role of Nucleolar Stress in the treatment of advanced pancreatic ductal adenocarcinoma. Reviewer's code: 03647295 Reviewer's country: Brazil Science editor: Ze-Mao Gong Date sent for review: 2016-10-29 20:44 Date reviewed: 2016-11-11 02:38

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
[ ] Grade A: Excellent	[ ] Grade A: Priority publishing	Google Search:	[ ] Accept
[ ] Grade B: Very good	[Y] Grade B: Minor language	[ ] The same title	[ ] High priority for
[Y] Grade C: Good	polishing	[ ] Duplicate publication	publication
[ ] Grade D: Fair	[ ] Grade C: A great deal of	[ ] Plagiarism	[ ] Rejection
[ ] Grade E: Poor	language polishing	[ Y ] No	[Y] Minor revision
	[ ] Grade D: Rejected	BPG Search:	[ ] Major revision
		[ ] The same title	
		[ ] Duplicate publication	
		[ ] Plagiarism	
		[ Y ] No	

## COMMENTS TO AUTHORS

Diwakarla et al aimed to review the current therapeutic approaches in pancreatic ductal adenocarcinoma as well as new target treatments, especially those associated to ribosome biogenesis. The manuscript is well written, although there is space for some improvements. My first consideration is about the title: two-thirds of the manuscript are not about the role of nucleolar stress in treatment. Thus, the authors are encouraged to revise the title to something more generic. The authors should consider a minor English revision (e.g. "back bones" in the abstract). Also, all gene names should be italicized, by convention. In the section "Genetic basis of PDAC" the authors mention KRAS, TP53, CDKN2A and SMAD4, citing Figure 1. However, not all these genes are not mentioned in this Figure. Please, consider to cite the Figure in another moment. In the light of the new treatment options (platinum salts and PARP inhibitors) to patients harboring BRCA2 or PALB2 mutations, this issue could be better discussed.